Prevalence and Risk of Mild Cognitive Impairment (MCI) in Low and Middle-Income Countries: A Systematic Review

Andrea M McGrattan^{1*}, Yueping Zhu², Connor D Richardson¹, Devi Mohan^{3,4}, Yee Chang Soh^{3,4}, Ayesha Sajjad⁵, Carla van Aller¹, Shulin Chen², Stella-Maria Paddick^{6,7}, Matthew Prina⁸, Mario Siervo⁹, Louise A Robinson¹ and Blossom CM Stephan¹⁰

¹ Population Health Sciences Institute, Newcastle University, UK

² Department of Psychology and Behavioral Science, Zhejiang University, Hangzhou, China

³ Global Public Health. Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Selangor, Malaysia.

⁴ South East Asia Community Observatory (SEACO), Monash University Malaysia, Segamat, Malaysia

⁵ Department of Epidemiology Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands.

⁶ Translational and Clinical Research Institute, Newcastle University, UK

⁷ Gateshead NHS Community Health Foundation Trust

⁸ Social Epidemiology Research Group, Health Service and Population Research Department, King's College London, London, UK

⁹ School of Life Sciences, The University of Nottingham Medical School, Nottingham, United Kingdom.

¹⁰ Institute of Mental Health, Division of Psychiatry and Applied Psychology, Nottingham University, UK.

***Corresponding author**

Dr Andrea McGrattan

Population Health Sciences Institute

Newcastle University

Biomedical Research Building

Campus for Ageing and Vitality

Newcastle upon Tyne

NE4 5PL

Tel: +44 (0) 191 208 5467

Email: andrea.mcgrattan@newcastle.ac.uk

Target Journal JAD

Word count (main body text): 4589

ABSTRACT

Introduction Mild Cognitive Impairment (MCI) is a cognitive state associated with increased risk of dementia. Little research on MCI exists from low-and middle-income countries (LMICs), despite high prevalence of dementia in these settings.

Objective This systematic review aimed to review epidemiological reports to determine the prevalence of MCI and its associated risk factors in LMICs.

Methods Medline, Embase and PsycINFO were searched from inception until November 2019. Eligible articles reported on MCI in population or community-based studies from LMICs. No restrictions on the definition of MCI used as long as it was clearly defined.

Results 4,621 articles were screened, and 78 retained. In total, n=23 different LMICs were represented; mostly from China (n=55 studies). Few studies from countries defined as lower-middle income (n=14), low income (n=4), or from population representative samples (n=4). There was large heterogeneity in how MCI was diagnosed; with Petersen criteria the most commonly applied (n=26). Prevalence of aMCI (Petersen criteria) ranged from 0.6% to 22.3%. Similar variability existed across studies using the International Working Group Criteria for aMCI (range 4.5% to 18.3%) and all-MCI (range 6.1% to 30.4%). Risk of MCI was associated with demographic (e.g. age), health (e.g. cardio-metabolic disease) and lifestyle (e.g. social isolation, smoking, diet and physical activity) factors.

Conclusion Outside of China, few MCI studies have been conducted in LMIC settings. There is an urgent need for population representative epidemiological studies to determine MCI prevalence in LMICs. MCI diagnostic methodology also needs to be standardised. This will allow for cross-study comparison and future resource planning.

Key words: Epidemiology, Low-and Middle-Income Country (LMIC), Mild Cognitive Impairment (MCI), Prevalence, Risk Factors, Systematic Review

INTRODUCTION

Mild Cognitive Impairment (MCI) defines an intermediate state of cognitive function between normal ageing and dementia. Numerous definitions for MCI exist and prevalence estimates vary (range <1% up to 56% across different studies and definitions) depending on population sampling (age, clinical vs population), MCI case definition and operationalisation of the component criterion for an MCI case diagnosis [1-7]. However, the majority of MCI research has been undertaken in high-income countries, namely North America, Europe and Australia. This raising questions of generalisability of findings to low-and middle-income countries (LMIC) which vary by wealth, culture, ethnicity, research capacity and infrastructure to support ageing populations.

Studies examining MCI prevalence in LMICs have produced conflicting results. For example, the 10/66 study reported a range of estimates (0.8 to 4.3%) of Petersen defined amnesic MCI (aMCI) [8] across sites in Cuba, the Dominican Republic, Peru, Venezuela, Mexico, China, India and Puerto Rico [9]. Findings from the World Health Organization's Study on Global Ageing and Adult Health reported an overall MCI prevalence of 15.3% (95%CI: 14.4-16.3) when applying the National Institute of Ageing-Alzheimer's Association (NIA-AA) criteria [10] across sites in China, Ghana, India, Mexico Russia, and South-Africa [11]; with the individual country prevalence estimates lower (e.g. 8.5% in South Africa [12]). It is not clear what is driving the differences. Within studies, the differences likely reflect variability in the profile of risk and protective factors across sites as well as cultural/ethnic perceptions of cognitive ageing and symptom reporting. Across studies, differences are likely due to heterogeneity in methodology e.g. differences in sample selection and the MCI criteria used for diagnosis.

While some have suggested that MCI as a mode of prodromal classification can have a limited role in clinical and epidemiological settings, others argue that MCI could be a pragmatic tool for identifying individuals who could benefit from risk reduction [13]. There is promising evidence to support dementia risk reduction interventions in HICs [14], with indications of similar opportunities in LMICs [15]. Determining how best to identify individuals with MCI and the prevalence of the condition in LMICs will have important implications for planning intervention trials, treatment strategies, budgeting and

public health surveillance. While several reviews on MCI have been conducted [1-7], to our knowledge none have focused specifically on LMIC settings. Therefore, the aim of this systematic review was to report on the population prevalence and risk factors for MCI in these settings. No restrictions were applied to the definition of MCI used as long as it was clearly defined.

MATERIALS AND METHODS

This review adhered to standard reporting guidelines [16] and full details of the MOOSE checklist [17] are in Appendix I. The review protocol can be made available by a member of the research team upon request.

Search Strategy

Medline, Embase and PsycINFO were searched from inception to the 10 January 2018, with updated searches run from 10 January 2018-6 November 2018 and from 6 November 2018-30 November 2019 (CR; See Supplementary Table 1 for the list of search terms).

Inclusion/Exclusion Criteria

Studies were included if: (1) the sample was from a LMIC, at the time of the study, as defined by The World Bank[18]; (2) the study reported population-level or community-based data; and, both cross-sectional and cohort study designs were included; (3) the study described how MCI had been mapped; (4) sample age was ≥ 50 years; and, (5) MCI prevalence was reported. No restrictions were placed on the definition of MCI used, language or publication date. Randomised controlled trials, case-control studies, unpublished studies, and conference abstracts were excluded. Studies were also excluded if, for analysis, cognitive groups (e.g. dementia and MCI groups) were combined or the sample restricted (e.g. studies investigating MCI in disease specific groups such as diabetics or in illiterate participants only). Reviews were also retained and the reference lists of these interrogated for any missed paper.

Data Analysis

Titles/abstracts were first screened, followed by the full text of any identified articles (CR and CVA). Where multiple publications using the same study were identified, these were retained for full text review and kept if they presented original findings. Disagreements were resolved by consensus or a third party (BCMS). Data including study characteristics, operationalisation of MCI criteria, and MCI prevalence estimates were independently extracted by four investigators (AMG [Chinese Studies], AS, BCMS and CVA).

Study quality (bias) was assessed using the tool developed by Hoy et al [19]. Nine items were selected related to representativeness of the study sample, methods for case definition, and the statistical calculation of MCI prevalence. Each risk of bias item was scored '0' (low risk) or '1' (high risk) of bias (total score range: 0 to 9).

Forest plots of the population prevalence estimates of MCI, defined using the most commonly applied criteria across the studies were created Prism-GraphPad 8 for Windows (GraphPad Software, San Diego, USA). This included plots for MCI defined using Petersen criteria (including all-MCI and aMCI; n=26 studies [9, 20-44]), International Working Group (IWG) criteria (n=14 studies [45-58]), or study specific criteria for Cognitive Impairment no Dementia (CIND; n=10 studies [59-68]). A meta-analysis was not possible due to large heterogeneity in methodology across the studies and the lack of key statistical information (i.e. confidence intervals for the MCI prevalence estimates) in most studies.

Role of the funding source

The review was completed as part of the NIHR Global Health Group: DePEC (Grant number: 16/137/62). AMG and BCMS have full access to the data and final responsibility to submit for publication.

RESULTS

Search Yields

The electronic search identified n=4,548 studies, with duplicates removed (See Figure 1). Following title/abstract screening, 162 studies were selected for full text review. This included a systemic review on MCI prevalence in China [7], where an additional n=48 studies in Mandarin were identified. These were added to the review giving a total of n=210 full text studies. From these, 73 studies were selected for inclusion. An updated electronic search in November 2019 yielded 972 studies, and an additional five were included (total n=78 studies). Two studies [66, 67] used the same dataset, but these were retained as they provided MCI prevalence estimates for different age groups.

Study Characteristics

Table 1 shows the characteristics of each study. Sample size ranged from n=120 [69] to n=32,715 [11]. Most studies included participants aged ≥ 60 years (n=46 studies [22, 25-30, 32, 35-42, 47, 52-56, 58, 60, 61, 65, 67, 68, 70-87]) or ≥ 65 years (n=16 studies [9, 23, 33, 44, 46, 48, 50, 51, 57, 62-64, 69, 88-90]). The remaining studies included participants aged ≥ 50 years (n=6 studies [11, 21, 59, 91-93]), ≥ 55 years (n=7 studies [24, 31, 34, 43, 94-96]), ≥ 70 years (n=1 study [49]), and ≥ 80 years (n=2 studies [20, 66]). One study [92] included only women.

As shown in Table 1, four studies [9, 11, 50, 64] analysed MCI prevalence for multiple countries. The majority of studies have been conducted in China (n=55 studies [9, 11, 20, 24, 26-45, 48, 51, 52, 54, 56-58, 62, 66-68, 72-84, 86, 87, 89, 90, 94-96]), followed by India (n=6 studies [9, 11, 25, 85, 91, 92]), Mexico (n=4 studies [9, 11, 22, 65]), Brazil (n=2 studies [59, 60]), Malaysia (n=2 studies [47, 53]), the Philippines (n=2 studies [61, 69]), Central African Republic (n=2 studies [50, 64]), South Africa (n=2 studies [11, 93]), Republic of Congo (n=2 studies [50, 64]), and one each in Colombia [21], Nigeria [23], Cuba [9], Dominican Republic [9], Peru [9], Venezuela [9], Georgia [46], Kazakhstan [55], Tanzania [49], Bulgaria [88], Ghana [11], Russia [11], Egypt [70] and Benin West-Africa [63]. Therefore, most studies (n=67 studies [9, 11, 20-22, 24, 26-45, 47, 48, 51-60, 62, 65-68, 71-84, 86-90, 94-96]) were from sites in upper middle-income countries, 14 studies [9, 11, 23, 25, 46, 50, 55, 61, 64, 70, 85, 91-93] were from sites in lower middle-income countries, and four studies [49, 50, 63, 64] were from sites in low-income countries. One study [9] included data collected during 2003-2007 from eight

sites, one of which was Puerto Rico. This country was declared high-income by the World Bank in 2002. Therefore, the prevalence data for Puerto Rico has been excluded. Only four studies [11, 44, 65, 93] selected participants from a representative country-wide sample. The remaining studies included a sample of community residents from a specific region, city or district(s).

Quality Assessment

The detailed quality assessment is reported in Table 2 of the supplementary material. Two studies [44, 93] obtained a low risk of bias score across all nine domains assessed, with the majority of studies (n=66 studies) only having high risk scores in 1-3 domains [9, 11, 21-43, 46, 48-51, 53-57, 60, 61, 63, 65-68, 70-73, 75-78, 80-86, 88-91, 94-96]. These were mostly related to a lack of, or unclear use of, randomisation procedures and that the study sample was unlikely to be representative of the national population.

MCI Criteria

As shown in Table 1, numerous criteria were used to diagnose MCI including (1) Petersen's criteria [8, 97-102] (n=26 studies [9, 20-44]); (2) IWG criteria [103] (n=14 studies [45-58]); (3) study specific criteria for CIND (n=10 studies [59-68]); (4) study specific criteria for MCI (n=13 studies [30, 70, 74-76, 79, 80, 84, 86, 89, 91, 94, 95]); (5) DSM-IV criteria [104] (n=8 studies [72, 77, 78, 81-83, 90, 96]); (6) MCI based on a score from a neuropsychological assessment tool (n=3 studies [69, 87, 92]); (7) NIA-AA criteria [10] (n=2 studies [11, 93]); or, (8) the European Consortium on Alzheimer's Disease (ECAD) criteria [105] (n=2 studies [85, 88]). A full description of the different MCI criteria applied across the studies is in Supplementary Tables 3 and 4.

Operationalising MCI criteria

Full details of how MCI criteria were operationalised (and any modifications that were made to mapping the original diagnostic criteria) are detailed below and outlined in Supplementary Table 5. Overall, MCI was diagnosed using one or more of the following criteria (1) subjective/informant cognitive or memory complaint; (2) global cognitive performance; (3) domain specific cognitive performance; (4) physical

functioning; (5) no dementia; and, (6) other factors (e.g. disease related co-morbidity). Additional assessments were used in 7/78 studies [24, 27, 45, 47, 51, 62, 70]. In four studies a Clinical Dementia Rating (CDR) score between 0 and 0.5 [27], or a score of 0.5 was needed for diagnosis of MCI [24, 45, 51]. In four studies [24, 47, 62, 70] it was required that cognitive impairment was independent of other factors such as depression.

Domain Specific MCI

Based on the cognitive domain test scores, 17 studies [9, 20-24, 26, 43, 45-48, 51-53, 70, 91] stratified MCI into different subtypes. This included non-amnesic MCI (naMCI; n=8 studies [22, 23, 43, 45-48, 51]), aMCI single domain (aMCI-SD; n=4 studies [22, 23, 43, 48]), multi-domain aMCI (aMCI-MD) (n=5 studies [22, 23, 43, 46, 48]), multi-domain non-amnesic MCI (naMCI-MD; n=4 studies) [22, 23, 46, 48], and single domain naMCI (naMCI-SD; n=3 studies [22, 23, 48]).

Subjective Cognitive/Memory Complaint

Cognitive/memory complaints were included as part of the MCI diagnosis in 57/78 studies [9, 11, 20-24, 26-29, 31-34, 36-43, 45, 47-56, 58-60, 62, 70, 72-76, 78-83, 85, 88, 90, 91, 93-95]. Complaint was typically required to be subjective and focused on memory (n=43 studies [9, 11, 20-22, 24, 26-28, 31-34, 36-43, 47, 48, 52, 53, 58-60, 62, 70, 72-74, 76, 78, 79, 81-83, 90, 95]) or cognition in general (n=11 studies [23, 45, 49-51, 54, 56, 75, 80, 85, 88]). In 25 studies, complaints could also be reported by an informant [22, 23, 27, 28, 44, 45, 47, 48, 51, 52, 54-56, 60, 62, 70, 72, 73, 75, 76, 80, 85, 91, 94, 95]. Thirty studies did not specify how cognitive/memory complaints were assessed or the information was not reported [20, 24-26, 29, 30, 43, 44, 46, 49, 50, 55, 57, 61, 63-69, 77, 84, 87-89, 92, 93, 96].

Global Cognitive Function

Global cognitive function was assessed in 61/78 studies [21-23, 25-34, 36-44, 46, 47, 50, 52-54, 57-70, 72-76, 78-83, 88-92, 95, 96]. In 33 studies [23, 25, 29, 32, 39-41, 50, 57-70, 74, 75, 79-83, 88, 90, 92, 95], global cognitive function was required to be impaired, while in 28 studies [21, 22, 26-28, 30, 31, 33, 34, 36-38, 42-44, 46, 47, 52-54, 72, 73, 76, 78, 89, 91, 94, 96] it was required to be preserved or

within normal limits. In total, 10 different neuropsychological assessment tools were used to assess global cognitive function including the Mini Mental State Examination (MMSE; n=40 studies [20, 22, 25-27, 30, 31, 33, 34, 36, 43, 47, 52-54, 57, 59, 60, 62, 66-69, 72, 74-76, 78, 80-83, 88-92, 95, 96]), the Montreal Cognitive Assessment (MoCA; n=10 studies [27, 29, 32, 39-41, 46, 58, 79, 89]), the Clinical Dementia Rating scale (CDR; n=5 studies [44, 61, 66, 67, 70]), the Community Screening Instrument for Dementia (CSI-D; n=3 studies [50, 63, 64]), the Consortium to Establish a Registry for Alzheimer's Disease battery (CERAD; n=2 studies [21, 91]), the Five Word Test (FWT; n=2 studies [63, 64]), the Cambridge Examination for Mental Disorders-Revised (CAMDEX-R; n=1 study [20]), the Identification and Intervention for Dementia in Elderly Africans (IDEA) cognitive screen (n=1 study [23]), The Memory Impairment Screen (MIS; n=1 study [88]), and the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE; n=1 study [65]). Of the studies using the MMSE, and with reported cut-off scores, 22 studies [26, 27, 30, 31, 33, 57, 59, 60, 62, 67, 72, 73, 75, 80-83, 89, 90, 94-96] used education specific cut-off scores, and 16 studies used a mixture of the following:

1. To demonstrate normal cognitive function: MMSE $\geq$ 24 (n=4 studies [43, 54, 76, 78]), MMSE one standard deviation (1SD) from norm (n=1 study [68]), MMSE $\geq$ 19 (n=2 studies [47, 53]), MMSE $\geq$ 23 (n=1 study [22]) and MMSE range 24-26 (n=1 study [36]); and,
2. To demonstrate cognitive impairment: MMSE $\leq$ 24 (n=2 studies [25, 92]), MMSE $\leq$ 26 (n=2 studies [34, 74]), MMSE $\leq$ 25 (n=1 study [88]), MMSE $\leq$ 27 (n=1 study [66]), and MMSE range 20-25 (n=1 study [69]).

Domain Specific Cognitive Function: Memory

Memory was individually assessed for impairment in 41 studies [9, 11, 20-24, 26-29, 37-53, 55, 56, 59, 60, 62, 65, 70, 73, 78, 88, 90, 91, 93]. Some studies used neuropsychological assessment tools to assess memory impairment. The MMSE (n=3 studies [20, 26, 52]), and the Wechsler Memory Scale (WMS; n=3 studies [27, 48, 62]) were the most frequently used, followed by the MIS (n=2 studies [22, 88]), the CSI-D (n=1 study [9]), the Cross-Cultural Cognitive Examination (CCCE; n=1 study [65]), and the Cambridge Mental Disorders of the Elderly Examination (CAMDEX) (n=1 study [20]). The remaining studies used individual memory tests, of which the Auditory-Verbal Learning Test (AVLT; n=6 studies

[43-45, 51, 53, 62]) was most often used followed by the CERAD 10 word learning test (n=5 studies [9, 11, 21, 49, 93]), the digit span test (n=4 studies [11, 12, 47, 53]), the Brief Cognitive Screening Battery (BCSB) delayed recall task (n=2 studies [59, 60]), the Fuld Object Memory Evaluation (FOME; n=1 study [45]), the stick test (n=1 study [45]), the Renminbi test (n=1 study [45]), the IDEA 10 word learning test (n=1 study [23]), the MoCA free delayed recall test (n=1 study [46]), the Rey-Osterrieth complex figure test (n=1 study [43]), RAVLT total learning (n=1 study [47]), RAVLT delayed recall (n=1 study [47]), the MMSE memory subtask (n=1 study [48]), WMS-III local memory test (n=1 study [70]), CDR memory score (n=1 study [70]), CCCE verbal memory (n=1 study [65]), and the free and cued selective reminding test (n=1 study [50]). Eighteen studies describe cut-off scores for impairment including: <1.5 SDs adjusted for age and education (n=8 studies [9, 21, 22, 43, 45, 48, 51, 78]), <1.5 SDs below norms (n=6 studies [27, 44, 46, 53, 62, 91]), <1 SD below norms (n=2 studies [47, 70]), <1 SD adjusted for age, education and country (n=2 studies [11, 93]), and, 1.5-2 SDs below the overall mean adjusted for age and education (n=1 study [56]).

Domain Specific Cognitive Function: Other Domains

Non-memory cognitive test performance was assessed in 26 studies [11, 22, 23, 25, 27, 43-51, 55, 56, 59, 60, 62, 65, 79, 85, 88, 91, 93]. Eight different test batteries were used including: the Wechsler Adult Intelligence Scale (WAIS; n=3 studies [27, 48, 62]), CERAD (n=1 study [88]), CSI-D (n=1 study [49]), the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-COG; n=1 study [22]), IDEA cognitive screen (n=1 study [23]), CAMCOG (n=1 study [25]), MOCA (n=1 study [46]), Malayalam version of Addenbrooke's Cognitive examination (m-ACE; n=1 study [85]), and the CCCE (n=1 study [65]). In addition, domain-specific tests (e.g. attention and executive function) were used, with the four most common being the verbal fluency test (n=10 studies [11, 43, 44, 50, 51, 59, 60, 62, 91, 93]), the Trail Making Test (TMT; n=7 studies [27, 43-46, 51, 62]), the Clock Drawing Test (CDT; n=5 studies [43, 44, 46, 47, 51]), and the Boston Naming Test (n=2 studies [43, 62]). Two studies [56, 79] stated that non-memory domains were assessed, however they did not describe which tests were used.

Dementia

Criteria used to exclude dementia included the DSM-IV (n=27 studies [20, 23, 25, 27, 34, 37, 44-46, 48-51, 55, 59, 61-64, 66-68, 70, 85, 88, 91, 92]), performance on a neuropsychological assessment battery (n=8 studies [22, 43, 47, 52, 56, 69, 87, 89]), a combination of cognitive test performance and evaluation of Activities of Daily Living (ADL)/ Instrumental Activities of Daily Living (IADL; n=4 studies [11, 21, 65, 93]), NINCDS-ADRDA criteria (n=3 studies [23, 37, 62]), ICD-10 criteria (n=1 study [25]), the 10/66 dementia algorithm (n=1 study [9]), diagnoses by a doctor (n=1 study [53]) or NIA-AA criteria (n=1 study [60]).

Functional Performance

Fifty-six studies reported that physical functioning, including ADL/IADL, were part of the assessment for MCI [9, 11, 20-28, 31-33, 36-38, 42-56, 59, 60, 62, 65-67, 72-76, 79-83, 85, 88, 90, 91, 93-95]. However, 26 of these studies did not report the method used to determine physical functioning status [24-26, 28, 32, 34, 36-38, 42, 43, 46, 48, 49, 56, 72, 73, 75, 76, 79-83, 94, 95]. Thirty-six studies [9, 11, 20, 21, 24-27, 31-33, 37, 38, 42, 45-50, 52-54, 62, 65-67, 73, 74, 88, 90, 95] exclusively assessed either ADL or IADL. The majority of studies required persevered ADL/IADL for a diagnosis of MCI, with only 13 studies [9, 11, 22, 41, 46, 53, 72, 75, 80-83, 91] allowing for subtle changes/mild functional impairment. In 26 studies, impairment in ADL/IADL was assessed using previous developed tools, of which the Katz ADL scale was the most often used (n=8 studies [11, 20, 22, 27, 47, 52, 53, 93]), followed by the Lawton and Brody scale (n=5 studies [21, 45, 47, 52, 53]), the Functional Activities Questionnaire (FAQ; n=4 studies [44, 51, 55, 60]), the CDR (n=2 studies [45, 51]), the CSI-D informant interview (n=2 studies [9, 50]), the Everyday Ability Scale for India (n=2 studies [85, 91]), the Barthel scale (n=1 study [21]), the Clinician Home Based Interview to assess Function (CHIF test; n=1 study [23]), and the IQCODE (n=1 study) [60].

MCI prevalence

The prevalence estimates reported in this review were all determined at the time of the study. However, one study [86] reported MCI prevalence at two time points (2010 and 2015). Across the different definitions used, 31 studies [11, 22, 23, 25, 27, 30, 31, 43-51, 55, 57, 69, 71, 75, 80, 84-89, 91, 93, 96]

calculated overall MCI prevalence, 47 studies [9, 20-24, 26, 28, 29, 32, 34-43, 45-48, 51-53, 56, 58, 70, 72-74, 76, 78, 79, 81-83, 90, 91, 94, 95] calculated aMCI prevalence, eight studies [22, 23, 43, 45-48, 51] calculated naMCI prevalence and 10 studies [59-68] calculated CIND prevalence. Two studies [44, 86] subtyped MCI by aetiology as defined by: MCI caused by prodromal Alzheimer's disease [44], MCI resulting from cerebrovascular disease [44], MCI with vascular risk factors [44], MCI with significant memory impairment [86], MCI with significant executive function impairment and relationship with cerebral vascular disease [86] and MCI caused by other factors [86]. As shown in Table 1, MCI prevalence ranged from 0.3% (95% CI: 0.1-0.5) in a sample from Mexico (n=2,944; ≥ 60 years; naMCI multiple domain, Petersen criteria) [22] to 63.3% in a sample from the Philippines (n=120; ≥ 65 years; MCI defined as an MMSE score 20-25 out of 30) [69]. Specifically, for Petersen criteria, prevalence of aMCI ranged from 0.6% (95%CI: 0.3-0.9) [9] to 22.3% [26]. Similar variability was seen across studies using the IWG Criteria for aMCI (range 4.5% [48] to 18.3% [58]; n=9 studies); IWG criteria for all-MCI (range 6.1% [50] to 30.4% [55]; n=10 studies); studies using CIND criteria (range 6.1% [59] to 47.4% [66]; n=10 studies), studies using study specific criteria to diagnose MCI (range 1.6% [86] to 27.7% [80]; n=13 studies); DSM-IV criteria (range 9.8% [83] to 33.0% [77]; n=8 studies); studies using neuropsychological tests (range 9.7% [87] to 63.3% [69]; n=3 studies); NIA-AA criteria (range 8.5% [93] to 15.3% [106]; n=2 studies) and European Consortium of AD criteria (range 6.7% [88] to 26.1% [85]; n=2 studies).

The forest plots in Figure 2 show the MCI prevalence estimates for Petersen defined all-MCI (Figure 2A) and aMCI (Figure 2B), the IWG criteria (Figure 2C) and criteria for CIND (Figure 2D). The plots show there is large variability in MCI prevalence across studies even when the same criteria are applied in the same country *albeit* in different samples. In contrast, prevalence estimates are generally, although not always, more consistent across countries in multi-site studies (n=4 studies [9, 11, 50, 64]) when the same methods are used (0.6%-4.6% [9]; 6.1%-7.2% [50]; 18.8%-25.0% [64]).

Associated Risk Factors

Risk factors for prevalent MCI were investigated in 64/78 studies [20-24, 26-45, 47, 48, 51-60, 62, 67-69, 72-76, 78-87, 89-93, 95, 96]. Two studies [53, 67] did not report risk factor information in the original article, however, risk factor data for the same cohort were later published in a separate article [107, 108]. In this scenario, we have added the risk factor information as documented in the most recent publication. One paper [27] reported additional vascular risk factor information in a separate article [109] and we have also included this data. Significant risk factors for MCI included increased age (n=46/64 studies [22, 23, 26-42, 44, 45, 48, 51, 54-58, 62, 67, 72-76, 78-82, 84, 89, 90, 92, 94, 96]), sex (n=41/64 studies; in 37 studies [22-24, 26, 28-30, 33, 34, 36, 38-42, 45, 48, 51, 54, 58, 62, 67-69, 72, 73, 76, 78, 81, 84, 86, 89, 90, 93-96] women had higher risk and in four studies [21, 27, 44, 87] men had higher risk), and low level of education (n=44/64 studies [20-23, 27-37, 39-45, 48, 51, 54-57, 62, 67, 72-76, 78-82, 84, 89, 90, 94]). Other significant risk factors included the presence of disease related co-morbidities (e.g. hypertension, stroke, coronary heart disease) [12, 20, 22, 34, 41-44, 48, 56, 60, 67, 84, 86, 89-91, 94], low monthly income/low economic status [27-29, 33, 36, 39-42, 62, 79, 90, 92], marital status (without spouse) [28, 33, 34, 41, 54, 62, 68, 75, 76, 78, 80, 84, 87, 90, 92], occupation (physical labour) [27, 28, 34, 37, 41, 44, 58, 74-76, 78, 81, 83], geographic area (rural location) [37, 51, 68], diabetes [34, 41-44, 48, 84, 86, 90, 91], alcohol consumption [20, 39, 72, 81, 85, 93, 94], high body mass index [22, 48, 86, 89, 94], living alone [28, 29, 32, 34, 36, 38, 72, 78, 79, 81], APOE E4 carrier [32, 94], low physical activity [28, 38, 39, 41, 54, 84], current or a history of smoking [26, 34, 39, 48, 72, 75, 84, 90, 91], sleep (poor) [26, 28, 38, 84], depression [22, 41, 90], and an introverted personality [29, 40, 58]. Protective factors included maintaining social contact with others [29, 43, 58, 76, 78] and following a healthy diet/consuming healthy dietary components [35, 40, 43, 81] or specifically drinking tea [26, 35, 43, 89]. **See supplementary Table 6 for full details of all risk factors reported across the different studies.**

DISCUSSION

This is the first systematic review, to our knowledge, focused on MCI prevalence and its risk factors specifically in LMICs. The results highlight that MCI research in LMICs is largely restricted to upper-middle income countries, namely China. Further, MCI research is characterised by wide variation in

population sampling, the case definition used for an MCI diagnosis, operationalisation of the component criterion and prevalence estimates. These differences make cross-study comparison extremely difficult and highlight the urgent need for consensus in how MCI is defined across different settings.

MCI prevalence ranged from 0.3% [22] to 63.3% [69]. This variability was not reduced when grouping prevalence estimates by case definition. However, as shown in Figure 2, there was a general pattern. Similar to what is observed in high income countries [110] we found that diagnostic criteria that are more restrictive and capture a single impairment (e.g. Petersen aMCI criteria; range 0.6% (95%CI: 0.3-0.9) [9] to 22.3% [26]) have generally lower prevalence estimates compared to more general criteria that capture broader dysfunction (e.g. CIND where the majority of studies $n=7/10$ reported a prevalence $>15\%$). Although it is important to note that estimated prevalence for specific criteria did vary considerably. In relation to age, across all definitions, MCI appears to be rare in the very young, i.e. people <50 years. Furthermore, aMCI (Petersen Criteria) and IWG generally have a lower prevalence in studies where people are aged ≥ 65 vs people aged ≥ 60 with the opposite trend observed for all MCI (Petersen Criteria) and CIND.

Regarding definition, across studies, the most widely applied criteria were Petersen defined aMCI ($n=26$ studies [9, 20-44]) requiring subjective/informant memory complaint, normal global cognitive function, impaired memory, preserved (or relatively preserved in later definitions) physical function and no dementia. Prevalence of aMCI ranged from 0.6% (95%CI: 0.3-0.9) [9] to 22.3% [26]. Similar variability was seen across studies using the IWG Criteria for aMCI (range 4.5% [48] to 18.3% [58]) and IWG criteria for all-MCI (range 30.4% [55] to 6.1% [50]). These results are in line with previous systematic reviews of MCI incorporating studies predominately from high-income countries [111]. Variability in prevalence is likely due to differences in sample characteristics (e.g. age, educational attainment and distribution of risk and protective factors) and methodology (e.g. test batteries used to assess cognitive and physical function, cut-off scores for impairment and whether the analyses were adjusted for factors such as age, sex and education) across studies. Indeed, of the studies that included multiple sites all

demonstrated that when the same methods were used to diagnose MCI, prevalence estimates were generally (although not always) more comparable across countries [9, 11, 50, 64].

Similar to findings in high-income countries, both modifiable and non-modifiable risks factors were identified for MCI. Key socio-demographic risk factors included increased age, sex (usually, but not always female) and low educational attainment. Modifiable health and lifestyle risk factors included, but were not limited to, smoking, presence of cardiovascular related diseases, social contact, occupation, physical activity and dietary related factors. These findings support the development of novel public health interventions to reduce risk of cognitive impairment targeting education, cardio-metabolic health and lifestyle factors that are applicable to the specific context of LMIC settings. However, a key knowledge gap highlighted by the review is the lack of research into context specific risk factors. Indeed, compared to high-income countries factors such as lifelong disadvantage, food insecurity, poverty, and absence of robust health and social care services might also be important in increasing risk of MCI and dementia in these settings.

Of note, is the scarcity of studies on MCI from countries classified as low-income (only n=4 studies [49, 50, 63, 64]). Further, no studies were identified from LMICs in the Middle East, with the exception of one study from Egypt [70]. As shown in Figure 3, most MCI research in LMICs has come from cohorts in the Far East (e.g. China and parts of Asia and South-Asia including Malaysia, Philippines and India), South America and the Caribbean (including Cuba, Dominican Republic, Mexico) and an increase in research in Africa (Tanzania, Nigeria, Central African Republic, Republic of Congo) only in the last five years (i.e. from 2015 onwards). Few studies have also been conducted in European LMICs with the exception of Bulgaria [88], Russia [106] and Georgia [46]. This lack of research into MCI could reflect the more recent demographic transition and population ageing in LMICs, highlighted by an increase in dementia-specific research in the past 10 years [112]. Also, across different LMIC settings there are high levels of low educational attainment/illiteracy in older people and there are often no norms for cognitive testing making MCI diagnosis challenging. Furthermore, there are typically very

few specialist clinicians able to supervise this type of work in LMIC settings, with the exception of some countries like China.

Strengths and Weaknesses

The study has a number of strengths. We undertook a wide literature search capturing many of the different definitions of MCI. This allowed for a more comprehensive synthesis of the types of criteria used to diagnose MCI across the many different LMICs. Some studies however could still have been missed if they defined MCI outside the scope of the search. There are some weaknesses. First, the electronic search was undertaken in English and therefore studies published in other languages, including those common in LMICs such as Spanish, Portuguese and French could have been missed if they were not recoded in EMBASE, Pubmed or PsycInfo. We minimised the risk of not capturing Chinese articles by including findings from a recent systematic review on MIC prevalence in China[7]. Structuring the search this way could possibly explain the large number of MCI studies captured from China compared to other LMICs. This difference could also be due to variability in research investment into ageing and dementia. Second, we focused only on cross-sectional studies that reported MCI prevalence estimates. Therefore, we did not investigate whether MCI is predictive of future dementia in LMICs or what the risk factors for incident MCI are. As such, we are unable to make recommendations as to which criteria are the most “useful”. This was beyond the scope of the review. Last, given the paucity of research into ageing and dementia in LMIC settings we included any population-based study in the review; and, only four were population-representative [11, 44, 65, 93]. MCI prevalence results in non-representative samples must be viewed with caution as they may be biased for example by sampling (e.g. difference in location such as urban vs. rural) and differences in the profile of risk/protective factors (e.g. demographic, health and socio-economic status).

Conclusion

Numerous definitions of MCI have been proposed [113]. Determining which, if any, are suitable for application in LMICs will require an in-depth evaluation of not only how well they capture people with

cognitive impairment, but also whether the condition is predictive of future dementia in these settings. To achieve this will require consensus on how MCI is defined particularly in settings with varying educational levels and amongst older people and varying cultural milieu and expectations resulting in challenges in MCI case identification. Nevertheless, given the high burden of dementia now seen in LMIC s, identification of these higher risk individuals at a stage where intervention could take place is likely to have a high impact on the burden of disease associated with cognitive impairment and dementia in these settings. Thus, to further understand MCI prevalence in these settings there is an urgent need for more high quality, population representative MCI prevalence studies, particularly in countries classified as low income.

Conflict of Interests / Disclosure Statement

The authors have no conflict of interest to report.

Acknowledgments (including sources of support)

This project was funded by a Newcastle-Monash Universities SEED award and as part of NIHR Global Group: DePEC (Grant Number: 16/137/62).

Contributor Statement

BCM conceptualised the study. CVA, CR, and YZ screened and selected the studies. AMG, AS, BCMS and CVA extracted the data. CVA and BCM drafted the initial manuscript, with a critical review by AMG. MS developed the forest plots. SMP, DM, YCS, MP, LR, MS, CR, SC, AS provided feedback and further revised the manuscript. All authors read and approved the final manuscript.

References

- [1] Bischkopf J, Busse A, Angermeyer MC (2002) Mild cognitive impairment--a review of prevalence, incidence and outcome according to current approaches. *Acta Psychiatr Scand* **106**, 403-414.
- [2] Nie H, Xu Y, Liu B, Zhang Y, Lei T, Hui X, Zhang L, Wu Y (2011) The prevalence of mild cognitive impairment about elderly population in China: A meta-analysis. **26**, 558-563.
- [3] Roberts R, Knopman DS (2013) Classification and epidemiology of MCI. *Clin Geriatr Med* **29**, 753-772.
- [4] Alexander M, Perera G, Ford L, Arrighi HM, Foskett N, Debove C, Novak G, Gordon MF (2015) Age-Stratified Prevalence of Mild Cognitive Impairment and Dementia in European Populations: A Systematic Review. *J Alzheimers Dis* **48**, 355-359.
- [5] Hu C, Yu D, Sun X, Zhang M, Wang L, Qin H (2017) The prevalence and progression of mild cognitive impairment among clinic and community populations: A systematic review and meta-analysis. *Int Psychogeriatr* **29**, 1595-1608.
- [6] Ward A, Arrighi HM, Michels S, Cedarbaum JM (2012) Mild cognitive impairment: disparity of incidence and prevalence estimates. *Alzheimers Dement* **8**, 14-21.
- [7] Xue J, Li J, Liang J, Chen S (2018) The Prevalence of Mild Cognitive Impairment in China: A Systematic Review. *Aging Dis* **9**, 706-715.
- [8] Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol* **56**, 303-308.
- [9] Sosa AL, Albanese E, Stephan BC, Dewey M, Acosta D, Ferri CP, Guerra M, Huang Y, Jacob KS, Jimenez-Velazquez IZ, Rodriguez JJ, Salas A, Williams J, Acosta I, Gonzalez-Viruet M, Hernandez MA, Shuran L, Prince MJ, Stewart R (2012) Prevalence, distribution, and impact of mild cognitive impairment in Latin America, China, and India: a 10/66 population-based study. *PLoS Med* **9**, e1001170.
- [10] Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* **7**, 270-279.
- [11] Vancampfort D, Stubbs B, Lara E, Vandenbulcke M, Swinnen N, Koyanagi A (2017) Mild cognitive impairment and physical activity in the general population: Findings from six low- and middle-income countries. *Exp Gerontol* **100**, 100-105.
- [12] Koyanagi A, Veronese N, Stubbs B, Vancampfort D, Stickley A, Oh H, Shin J, Jackson S, Smith L, Lara E (2019) Food Insecurity Is Associated with Mild Cognitive Impairment among Middle-Aged and Older Adults in South Africa: Findings from a Nationally Representative Survey. *Nutrients* **11**, 749.
- [13] Saunders S, Ritchie K, Russ TC, Muniz-Terrera G, Ritchie CW (2018) Evolution and future directions for the concept of mild cognitive impairment. *Int Psychogeriatr* **30**, 1431-1434.
- [14] Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, Cooper C, Fox N, Gitlin LN, Howard R, Kales HC, Larson EB, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbaek G, Teri L, Mukadam N (2017) Dementia prevention, intervention, and care. *Lancet* **390**, 2673-2734.
- [15] Mukadam N, Sommerlad A, Huntley J, Livingston G (2019) Population attributable fractions for risk factors for dementia in low-income and middle-income countries: an analysis using cross-sectional survey data. *Lancet Glob Health* **7**, e596-e603.
- [16] Moher D, Liberati A, Tetzlaff J, Altman DG, medicine PGJP (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* **6**, e1000097.
- [17] Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for

- reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* **283**, 2008-2012.
- [18] WBG, Low and middle income - income level, The World Bank Group, <https://data.worldbank.org/income-level/low-and-middle-income>, Accessed 25/1/2018.
 - [19] Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R (2012) Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. *J Clin Epidemiol* **65**, 934-939.
 - [20] Hai S, Dong B, Liu Y, Zou Y (2012) Occurrence and risk factors of mild cognitive impairment in the older Chinese population: a 3-year follow-up study. *Int J Geriatr Psychiatry* **27**, 703-708.
 - [21] Henao-Arboleda E, Aguirre-Acevedo DC, Munoz C, Pineda DA, Lopera F (2008) Prevalence of mild cognitive impairment, amnesic-type, in a colombian population. [Spanish]. *Rev Neurol* **46**, 709-713.
 - [22] Juarez-Cedillo T, Sanchez-Arenas R, Sanchez-Garcia S, Garcia-Pena C, Hsiung GYR, Sepehry AA, Beattie BL, Jacova C (2013) Prevalence of mild cognitive impairment and its subtypes in the Mexican population. *Dement Geriatr Cogn Disord* **34**, 5-6.
 - [23] Ogunniyi A, Adebisi AO, Adediran AB, Olakehinde OO, Siwoku AA (2016) Prevalence estimates of major neurocognitive disorders in a rural Nigerian community. *Brain Behav* **6**, e00481.
 - [24] Qiu CJ, Tang MN, Zhang W, Han HY, Dai J, Lu J, Wu S, Wang SH, Chen JM, Guo LJ, Ding YQ, Li SX, Liu XH (2003) The prevalence of mild cognitive impairment among residents aged 55 or over in Chengdu area. [Chinese]. *Chin J Epidemiol* **24**, 1104-1107.
 - [25] Tiwari SC, Srivastava G, Tripathi RK, Pandey NM, Agarwal GG, Pandey S, Tiwari S (2013) Prevalence of psychiatric morbidity amongst the community dwelling rural older adults in northern India. *Indian J Med Res* **138**, 504-514.
 - [26] Wang T, Xiao S, Chen K, Yang C, Dong S, Cheng Y, Li X, Wang J, Zhu M, Yang F, Li G, Su N, Liu Y, Dai J, Zhang M (2017) Prevalence, Incidence, Risk and Protective Factors of Amnesic Mild Cognitive Impairment in the Elderly in Shanghai. *Curr Alzheimer Res* **14**, 460-466.
 - [27] Xu S, Xie B, Song M, Yu L, Wang L, An C, Zhu Q, Han K, Zhao X, Zhang R, Dong L, Chai N, Gao Y, Zhang Q, Wang X (2014) High prevalence of mild cognitive impairment in the elderly: a community-based study in four cities of the Hebei province, china. *Neuroepidemiology* **42**, 123-130.
 - [28] Pan H, Wang J, Wu M, Cheng J (2012) Study on prevalence rate and quality of life of elderly patients with mild cognitive impairment in community. *Chin J Prac Nurs* **29**, 6-9.
 - [29] Gao LW, Jiang L, Gao YS, Nie HW, Y X (2011) Prevalence of mild cognitive impairment and its risk factors among elderly people in Canglang District of Suzhou City. *J Occup Health* **27**, 2676-2678.
 - [30] Huang LJ, Han JF, Liu AP, B L (2007) The study and analysis on mild cognitive impairment of the elderly in communities. *Mod Nurs* **13**, 2678-2680.
 - [31] Lao ML, Zhang HY, Luo G, Yi XN, Huang YD, Wu ZH (2011) Prevalence of mild cognitive impairment among 55-years old or over individuals in Hainan Island. *Hainan Med J* **22**, 112-114.
 - [32] Liao B, Gao M, Xiong LH, Yi GP, Li Y, Wan SL, al. e (2012) The early evaluation and intervention strategies of mild cognitive impairment in Yichun area. *J Yichun Coll* **24**, 77-79.
 - [33] Guo M, Gao L, Zhang G, Li Y, Xu S, Wang Z, Qu Q, Guo F (2012) Prevalence of dementia and mild cognitive impairment in the elderly living in nursing and veteran care homes in Xi'an, China. *J Neurol Sci* **312**, 39-44.
 - [34] Qin HY, Chen DH, ZW Q (2014) Investigation of mild cognitive impairment and its risk factors among 55 years old and above residents in Shanghai. *J Clin Psychiatry* **24**, 155-158.
 - [35] Song XZ, Chen JH, LP H (2012) Investigation on correlation between prevalence of the mild cognitive impairment and eating habit in elderly in the communities of Shunde-city. *Int Med Health Guid News* **18**, 1715-1718.

- [36] Su XB, Hua QZ, Zhang L, LI NN, Chen JH, LP Z (2013) Influencing factors of mild cognitive impairment of seniors in communitiew of Xi'an. *J Nurs* **20**, 6-9.
- [37] Tang Z, Zhang XQ, Wu XG, Liu HJ, Diao LJ, Guan SC, al. e (2007) Prevalence of the mild cognitive impairment among eldrly in Beijing. *Chin Ment Health J* **21**, 116-118.
- [38] Tong JF, Guo SY, Tao XJ, Guo JX, Tian Y, Xia BJ, al. e (2013) The elderly patients with mild cognitive impairment in the community of Tangshan. *Chin J Helth Psychol* **21**, 1642-1644.
- [39] Yin SQ, Nie HW, Y X (2011) The prevalence and risk factors of mild cognitive impairment among the aged in Huzhou. *Chin Gen Pract* **14**, 4145-4147.
- [40] Zhu KH, H L (2015) Analysis of influencing factors of mild cognitive impairment in elderly population. *Chin J Pract Nerv Dis* **18**, 52-54.
- [41] Zhang Y (2011) The study on the present situation investigating risk factors and early intervention of mild cognitive impairment in the elderly, MSc Thesis. *Soochow University*.
- [42] Wang Q (2012) A study on the prevalence and risk factors of mild cognitive impairment among the elderly in Tianjin community, MSc Thesis. *Tianjin Medical University*.
- [43] Li X, Ma C, Zhang J, Liang Y, Chen Y, Chen K, Wang J, Zhang Z, Wang Y, Beijing Ageing Brain Rejuvenation I (2013) Prevalence of and potential risk factors for mild cognitive impairment in community-dwelling residents of Beijing. *J Am Geriatr Soc* **61**, 2111-2119.
- [44] Jia J, Zhou A, Wei C, Jia X, Wang F, Li F, Wu X, Mok V, Gauthier S, Tang M, Chu L, Zhou Y, Zhou C, Cui Y, Wang Q, Wang W, Yin P, Hu N, Zuo X, Song H, Qin W, Wu L, Li D, Jia L, Song J, Han Y, Xing Y, Yang P, Li Y, Qiao Y, Tang Y, Lv J, Dong X (2014) The prevalence of mild cognitive impairment and its etiological subtypes in elderly Chinese. *Alzheimers Dement* **10**, 439-447.
- [45] Ding D, Zhao Q, Guo Q, Meng H, Wang B, Luo J, Mortimer JA, Borenstein AR, Hong Z (2015) Prevalence of mild cognitive impairment in an urban community in China: a cross-sectional analysis of the Shanghai Aging Study. *Alzheimers Dement* **11**, 300-309 e302.
- [46] Janelidze M, Mikeladze N, Bochorishvili N, Dzagnidze A, Kapianidze M, Mikava N, Khatiasvili I, Mirvelashvili E, Shiukashvili N, Lynch J, Nadareishvili Z (2018) Mild Cognitive Impairment in Republic of Georgia. *Gerontol Geriatr Med* **4**, 1-10.
- [47] Lee LK, Shahar S, Chin AV, Mohd Yusoff NA, Rajab N, Aziz SA (2012) Prevalence of gender disparities and predictors affecting the occurrence of mild cognitive impairment (MCI). *Arch Gerontol Geriatr* **54**, 185-191.
- [48] Ma F, Wu T, Zhao J, Ji L, Song A, Zhang M, Huang G (2016) Prevalence of mild cognitive impairment and its subtypes among Chinese older adults: Role of vascular risk factors. *Dement Geriatr Cogn Disord* **41**, 261-272.
- [49] Paddick SM, Kisoli A, Samuel M, Higginson J, Gray WK, Dotchin CL, Longdon AR, Teodorczuk A, Chaote P, Walker RW (2015) Mild cognitive impairment in rural Tanzania: Prevalence, profile, and outcomes at 4-year follow-up. *Am J Geriatr Psychiatry* **23**, 950-959.
- [50] Pilleron S, Jesus P, Desport JC, Mbelesso P, Ndamba-Bandzouzi B, Clement JP, Dartigues JF, Preux PM, Guerchet M (2015) Association between mild cognitive impairment and dementia and undernutrition among elderly people in Central Africa: some results from the EPIDEMCA (Epidemiology of Dementia in Central Africa) programme. *Br J Nutr* **114**, 306-315.
- [51] Rao D, Luo X, Tang M, Shen Y, Huang R, Yu J, Ren J, Cheng X, Lin K (2018) Prevalence of mild cognitive impairment and its subtypes in community-dwelling residents aged 65 years or older in Guangzhou, China. *Arch Gerontol Geriatr* **75**, 70-75.
- [52] Su X, Shang L, Xu Q, Li N, Chen J, Zhang L, Zhang L, Hua Q (2014) Prevalence and predictors of mild cognitive impairment in Xi'an: a community-based study among the elders. *Plos One* **9**, e83217.
- [53] Vanoh D, Shahar S, Din NC, Omar A, Vyrn CA, Razali R, Ibrahim R, Hamid TA (2016) Predictors of poor cognitive status among older Malaysian adults: baseline findings from the LRGS TUA cohort study. *Aging Clin Exp Res* **29**, 173-182.

- [54] Fang GZ, Chen XP, LJ Y (2009) The prevalence rate of mild cognitive impairment and its related factors in community elderly in Hangzhou. *Chin J Ger* **28**, 512- 515.
- [55] Tsoy RT, Turuspekova ST, Klipitskaya NK, Mereke A, Cumming RG (2019) Prevalence of Mild Cognitive Impairment Among Older People in Kazakhstan and Potential Risk Factors: A Cross-sectional Study. *Alzheimer Dis Assoc Disord* **33**, 136-141.
- [56] Fang H, JH S (2015) Investigation of the elderly with mild cognitive impairment in Shanghai Zhoujiaqiao Community. *Med Health Care* **23**, 5-8.
- [57] Sun HY, Qu QM, Liu J, Zhang J, Guo X, Jia L, al. e (2016) The epidemiological study of ethnic disparity in risk factors for mild cognitive impairment between Mongolia and Han population in baotou, Inner Mongolia. *J Apoplexy Nerv Dis* **33**, 454-456.
- [58] Zhang JA, Jiang H, Wang FC, LL G (2013) Investigation and Analysis on mild cognitive impairment among the elderly in the communities of Taicang city. *Pract Geriatr* **27**, 859-862.
- [59] Brucki SMD, Nitrini R (2014) Cognitive impairment in individuals with low educational level and homogeneous sociocultural background. *Dement Neuropsychol* **8**, 345-350.
- [60] Cesar KG, Brucki SMD, Takada LT, Nascimento LFC, Gomes CMS, Almeida MCS, Oliveira MO, Porto FHG, Senaha MLH, Bahia VS, Silva TBL, Ianof JN, Spindola L, Schmidt MT, Jorge MS, Vale PHF, Cecchini MA, Cassimiro L, Soares RT, Goncalves MR, Martins ACS, Dare P, Smid J, Porto CS, Carthery-Goulart MT, Yassuda MS, Mansur LL, Nitrini R (2016) Prevalence of cognitive impairment without dementia and dementia in Tremembe, Brazil. *Alzheimer Dis Assoc Disord* **30**, 264-271.
- [61] Dominguez J, Fe de Guzman M, Reandelar M, Thi Phung TK (2018) Prevalence of Dementia and Associated Risk Factors: A Population-Based Study in the Philippines. *J Alzheimers Dis* **63**, 1065-1073.
- [62] Fei M, Qu YC, Wang T, Yin J, Bai JX, Ding QH (2009) Prevalence and distribution of cognitive impairment no dementia (CIND) among the aged population and the analysis of socio-demographic characteristics: The community-based cross-sectional study. *Alzheimer Dis Assoc Disord* **23**, 130-138.
- [63] Guerchet M, Houinato D, Paraiso MN, von Ahnen N, Nubukpo P, Otto M, Clement JP, Preux PM, Dartigues JF (2009) Cognitive impairment and dementia in elderly people living in rural Benin, west Africa. *Dement Geriatr Cogn Disord* **27**, 34-41.
- [64] Guerchet M, M'Belesso P, Mouanga AM, Bandzouzi B, Tabo A, Houinato DS, Paraiso MN, Cowppli-Bony P, Nubukpo P, Aboyans V, Clement JP, Dartigues JF, Preux PM (2010) Prevalence of dementia in elderly living in two cities of Central Africa: the EDAC survey. *Dement Geriatr Cogn Disord* **30**, 261-268.
- [65] Mejia-Arango S, Gutierrez LM (2011) Prevalence and incidence rates of dementia and cognitive impairment no dementia in the Mexican population: data from the Mexican Health and Aging Study. *J Aging Health* **23**, 1054-1074.
- [66] Shi Z, Zhang Y, Yue W, Liu M, Huo YR, Liu S, Liu S, Xiang L, Liu P, Lu H, Wang J, Ji Y (2013) Prevalence and clinical predictors of cognitive impairment in individuals aged 80 years and older in rural China. *Dement Geriatr Cogn Disord* **36**, 171-178.
- [67] Zhang Y, Shi Z, Liu M, Liu S, Yue W, Liu S, Xiang L, Lu H, Liu P, Wisniewski T, Wang J, Ji Y (2014) Prevalence of cognitive impairment no dementia in a rural area of Northern China. *Neuroepidemiology* **42**, 197-203.
- [68] Lei M, Huang W, Yang J, Gao L, Wei L, al. e (2008) Prevalence of mild cognitive impairment old people in urban and rural areas of Guizhou province. *Chin Ment Health J* **22**, 387-391.
- [69] Inocian E, Patalagsa JG (2016) Cognitive impairment in older people living in the community. *Nurs Older People* **28**, 25-30.
- [70] Khedr E, Fawi G, Abbas MAA, Mohammed TA, El-Fetoh NA, Al Attar G, Noaman M, Zaki AF (2015) Prevalence of mild cognitive impairment and dementia among the elderly population of qena governorate, upper Egypt: A community-based study. *J Alzheimers Dis* **45**, 117-126.

- [71] Ding D, Zhao Q, Guo Q, Meng H, Wang B, Luo J, Mortimer JA, Borenstein AR, Hong Z (2015) Prevalence of mild cognitive impairment in an urban community in China: A cross-sectional analysis of the Shanghai Aging Study. *Alzheimers Dement* **11**, 300-309.e302.
- [72] Guo XY, Zhao LM, Li XM, Q Y (2013) Prevalence of mild cognitive impairment among rural Chinese elderly. *Chin J Mult Organ Dis Elderly* **12**, 904-907.
- [73] Huang RY, Tang MN, Ma C, Guo YB, Han HY, Huang JM, al. e (2008) The prevalence of mild cognitive impairment of residents aged 60 years and over in the urban and rural areas in Guangdong. *Chin J Nerv Ment Dis* **34**, 533-537.
- [74] Li J (2013) Survey of mild cognitive impairment in old people in community of Jinan city. *Chin Nurs Research* **27**, 2196-2197.
- [75] Wang ZQ, Zhuang MH, Lin YQ, Ding CH, H W (2014) The study on present situation investigation of mild cognitive impairment among elderly people in Zhoushan Island city. *Zhejiang Med J* **8**, 707-709.
- [76] Wu B, Zhang LY, Su YL, Dang YH, JX H (2012) Investigation on mild cognitive impairment among elderly in urban community of Xi'an. *Chin J Rehabil Theory Pract* **18**, 605-607.
- [77] Zhang WX, Li CP, Tian F, Wang Y, Liang YJ, X L (2015) The value of MoCA (Beijing) in screening mild cognitive impairment among old people in rural. *Chin J Gerontol* **35**, 4016-4018.
- [78] Zhang XQ, H Z (2014) Prevalence and factors associated with mild cognitive impairment among the elderly in Changsha Communities. *Chin Gen Pract* **17**, 1031-1035.
- [79] Zhao CS, Gao L, JN F (2015) Present situation and risk factors of mild cognitive impairment of 60-years old or over people in Jilin area. *Chin Rural Health Serv Adm* **35**, 1434-1437.
- [80] Zhou DM, Chen Q, Sui CY, M Y (2016) Investigation on the prevalence of mild cognitive impairment in the elderly in Changji city. *Chin Community Doct* **32**, 178-183.
- [81] Zhou DS, Xu YE, ZM C (2011) Prevalence of mild cognitive impairment among the elderly. *Chin J Public Health* **27**, 1375-1377.
- [82] Zhou XH, Zhu XQ, Barhematy K, Yue YH, Zhao RJ, Xing SF, al. e (2009) Cross-sectional study of the mild cognitive impairment among elderly in Xinjiang Uygur and Han ethnic groups. *Chin J Geriatr* **28**, 865-869.
- [83] Zhu XQ, Zhou XH, Barheimaty K, Yue YH, Zhao RJ, Xing SF, al. e (2009) Study of prevalence of the mild cognitive impairment among elderly in the communities of Urumqi city. *J Xinjiang Med Univ* **32**, 578-584.
- [84] Zhu YP, Chen MF, BH Z (2013) A prevalence study on mild cognitive impairment among elderly population in Zhejiang province. *Chin J Epidemiol* **34**, 475-477.
- [85] Mohan D, Iype T, Varghese S, Usha A, Mohan M (2019) A cross-sectional study to assess prevalence and factors associated with mild cognitive impairment among older adults in an urban area of Kerala, South India. *BMJ Open* **9**, e025473.
- [86] Lu H, Wang X-D, Shi Z, Yue W, Zhang Y, Liu S, Liu S, Zhao L, Xiang L, Zhang Y, Guan Y, Su W, Li Z, Wang J, Wisniewski T, Ji Y (2019) Comparative analysis of cognitive impairment prevalence and its etiological subtypes in a rural area of northern China between 2010 and 2015. *Sci Rep* **9**, 851.
- [87] Ruan Q, Xiao F, Gong K, Zhang W, Zhang M, Ruan J, Zhang X, Chen Q, Yu Z (2020) Prevalence of Cognitive Frailty Phenotypes and Associated Factors in a Community-Dwelling Elderly Population. *J Nutr Health Aging* **24**, 172-180.
- [88] Dimitrov I, Tzourio C, Milanov I, Deleva N, Traykov L (2012) Prevalence of dementia and mild cognitive impairment in a Bulgarian urban population. *Am J Alzheimers Dis Other Dement* **27**, 131-135.
- [89] Chu AQ, Liang XN, Chen YH, Gu PF, HW Q (2015) Prevalence and risk factors of mild cognitive impairment and dementia in community elderly. *Chin J of Clin Neuro* **23**, 673-677.
- [90] Xiong Y, Miao RJ, Wang QQ, Zhou LJ, Gao L, F M (2013) Prevalence and influencing factors of MCI among community elderly in Tianjin city. *Chin J Public Health* **29**, 1-4.

- [91] Das SK, Bose P, Biswas A, Dutt A, Banerjee TK, Hazra AM, Raut DK, Chaudhuri A, Roy T (2007) An epidemiologic study of mild cognitive impairment in Kolkata, India. *Neurology* **68**, 2019-2026.
- [92] Saha SK, Sanyal D, Bhattacharyya A, Bhattacharyya R, Barman N, Mukherjee A (2010) A study on cognitive status of 50 years and above aged non-demented women in a rural area of West Bengal. *J Indian Med Assoc* **108**, 726-729.
- [93] Koyanagi A, Veronese N, Stubbs B, Vancampfort D, Stickley A, Oh H, Shin JI, Jackson S, Smith L, Lara E (2019) Food Insecurity Is Associated with Mild Cognitive Impairment among Middle-Aged and Older Adults in South Africa: Findings from a Nationally Representative Survey. *Nutrients* **11**, 749.
- [94] Wang ZZ, Liu L, Huang YQ, Ding L, WR M (2016) The status of mild cognitive impairment in the Hui and Han people aged 55 years and above in Ningxia. *Chin J Gerontol* **36**, 4601-4603.
- [95] Wang ZZ, Ding L, Liu L, Li T, Ma WR, JL Z (2013) The present situation of mild cognitive impairment among 55-years old or over individuals of Hui and Han nationalities and its relationship with hormone. *Chin J Nerv Ment Dis* **39**, 427-430.
- [96] Hu R, Zhao SG, Wang DS, Wen SR, Niu GM, al. e (2012) A prevalence study on mild cognitive impairment among elderly population of Mongolian and Han nationalities in a pastrial area of Inner Mongolia. *Chin J Epidemiol* **33**, 364-367.
- [97] Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. *J Intern Med* **256**, 183-194.
- [98] Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L (2014) Mild cognitive impairment: a concept in evolution. *J Intern Med* **275**, 214-228.
- [99] Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. *Arch Neurol* **58**, 1985-1992.
- [100] Petersen RC, Morris JC (2005) Mild cognitive impairment as a clinical entity and treatment target. *Arch Neurol* **62**, 1160-1163.
- [101] Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG (1997) Aging, memory, and mild cognitive impairment. *Int Psychogeriatr* **9**, 65-69.
- [102] Petersen RC, Stevens JC, Ganguli M, Tangelos EG, Cummings JL, DeKosky ST (2001) Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* **56**, 1133-1142.
- [103] Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O (2004) Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. *J Intern Med* **256**, 240-246.
- [104] Bell CC (1994) DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. *JAMA* **272**, 828-829.
- [105] Portet F, Ousset PJ, Visser PJ, Frisoni GB, Nobili F, Scheltens P, Vellas B, Touchon J (2006) Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. *J Neurol Neurosurg Psychiatry* **77**, 714-718.
- [106] Vancampfort D, Stubbs B, Firth J, Smith L, Swinnen N, Koyanagi A (2019) Associations between handgrip strength and mild cognitive impairment in middle-aged and older adults in six low- and middle-income countries. *Int J Geriatr Psychiatry* **34**, 609-616.
- [107] Chong CP, Shahar S, Haron H, Din NC (2019) Habitual sugar intake and cognitive impairment among multi-ethnic Malaysian older adults. *Clin Interv Aging* **14**, 1331-1342.
- [108] Zhang Y, Guan Y, Shi Z, Yue W, Liu S, Liu S, Lu H, Zhao L, Zhang Y, Su W, Ji Y (2019) Sex Differences in the Prevalence of and Risk Factors for Cognitive Impairment No Dementia among the Elderly in a Rural Area of Northern China: A Population-Based Cross-Sectional Study. *Neuroepidemiology* **52**, 25-31.

- [109] Wang Y, Song M, Yu L, Wang L, An C, Xun S, Zhao X, Gao Y, Wang X (2015) Mild cognitive impairment: vascular risk factors in community elderly in four cities of Hebei Province, China. *PLoS One* **10**, e0124566.
- [110] Stephan BC, Matthews FE, McKeith IG, Bond J, Brayne C, Medical Research Council Cognitive F, Aging S (2007) Early cognitive change in the general population: how do different definitions work? *J Am Geriatr Soc* **55**, 1534-1540.
- [111] Pessoa RMP, Bomfim AJL, Ferreira BLC, Chagas MHN (2019) Diagnostic criteria and prevalence of mild cognitive impairment in older adults living in the community: a systematic review and meta-analysis. *Arch Clin Psychiatry (São Paulo)* **46**, 72-79.
- [112] Patterson C, World Alzheimer Report 2018 - The state of the art of dementia research: New frontiers, <https://www.alz.co.uk/research/WorldAlzheimerReport2018.pdf>, Accessed 25/07/2020.
- [113] Matthews FE, Stephan BC, McKeith IG, Bond J, Brayne C, Medical Research Council Cognitive F, Ageing S (2008) Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree? *J Am Geriatr Soc* **56**, 1424-1433.
- [114] Jia JP, Zhou AH, Wei CB, Jia XF, Wang F, Li F, al. e (2014) The prevalence of mild cognitive impairment and its etiological subtypes in elderly Chinese. *Alzheimers Dement* **10**, 439-447.

Table 1 Study characteristics and MCI prevalence arranged by definition (ordered by age [lowest to highest])

Author	Location	Income Class	Age (years)	Summary population characteristics	Mild cognitive impairment (MCI)			
					MCI definition	Total sample size	Cases	Prevalence % (95% CI)
MCI ACCORDING TO PETERSEN CRITERIA[8, 99, 101, 102] (n=26 studies)								
Henao-Arboleda, 2008 [21]	Columbia	UMIC	≥50	Residents of metropolitan area of Medellin	aMCI	848	82	9.7 (7.6 - 11.7)
Lao, 2011[31]	China	UMIC	≥ 55	Non-demented residents of Hainan province	MCI	7665	326	4.25 (3.80-4.68)
Li, 2013 [43]	China	UMIC	≥55	Non-demented residents of Beijing with an MMSE≥24 (The Beijing Ageing Brain Rejuvenation Initiative: BABRI)	All MCI	1,020	160	15.7
					aMCI-SD	1,020	65	6.4
					aMCI-MD	1,020	38	3.7
					naMCI	1,020	57	5.6
Qin, 2014[34]	China	UMIC	≥ 55	Non-demented residents of Shanghai	aMCI	4086	612	14.98 (13.88-16.02)
Qiu, 2003 [24]	China	UMIC	≥ 55	Non-demented residents of Chengdu	aMCI	3910	92	2.40 (1.88-2.80)
Gao, 2011[29]	China	UMIC	≥ 60	Non-demented residents of a community of Suzhou	aMCI	1773	243	13.71 (12.1-15.22)
Huang, 2008[73]	China	UMIC	≥ 60	Non-demented residents of Guangzhou	aMCI	4697	257	5.47(4.82-6.09)
Juarez-Cedillo, 2013 [22]	Mexico	UMIC	≥60	Residents, registered with family medicine units (IMSS), of Mexico City	All MCI	2,944	190	6.5 (5.6 - 7.4)
					aMCI-SD	2,944	71	2.4 (1.9 - 3.0)
					aMCI-MD	2,944	75	2.6 (2.0 - 3.1)
					naMCI-SD	2,944	35	1.2 (0.8 - 1.6)
					naMCI-MD	2,944	9	0.3 (0.1 - 0.5)
Liao , 2012[32]	China	UMIC	≥ 60	Non-demented residents of Yichun	aMCI	399	41	10.28 (7.30-13.10)
Pan, 2012 [28]	China	UMIC	≥ 60	Non-demented residents of Jinhua	aMCI	897	154	17.17 (14.7-19.51)
Song, 2012[35]	China	UMIC	≥ 60	Non-demented residents of a district of Foshan	aMCI	2279	167	7.33 (6.26-8.34)
Su, 2013[36]	China	UMIC	≥ 60	Non-demented residents of Xian	aMCI	796	145	18.22(15.53-20.76)
Tang, 2007[37]	China	UMIC	≥ 60	Non-demented residents of Beijing	aMCI	1865	217	11.60(10.18-13.02)
Tiwari, 2013[25]	India	LMIC	≥60	Residents of Malihabad and Bakshi Ka Talab of Lucknow district of the State of Uttar Pradesh	All MCI	2,146	98	4.6 (3.7 - 5.5)
Tong, 2013[38]	China	UMIC	≥ 60	Non-demented residents of Tangshan	aMCI	1575	200	12.7
Wang, 2012[42]	China	UMIC	≥ 60	Non-demented residents of Tianjin	aMCI	3678	408	11.1
Wang, 2017[26]	China	UMIC	≥60	Residents of rural and urban areas in Shanghai	aMCI	1,005	224	22.3
Xu, 2014[27]	China	UMIC	≥60	Non-demented residents of the Hebei province	All MCI	2,426	526	21.3 (19.2 - 23.1) ‡
Yin, 2011[39]	China	UMIC	≥ 60	Non-demented residents of Huzhou	aMCI	2164	310	14.33 (12.85-15.73)
Zhang, 2011[41]	China	UMIC	≥ 60	Non-demented residents of Suzhou	aMCI	5388	691	12.8
Zhu and Li, 2015[40]	China	UMIC	≥ 60	Non-demented residents of some communities of Xinyang	aMCI	1755	245	13.96 (12.34-15.50)
Jia, 2014[114]	China	UMIC	≥ 65	Non-demented residents of 5 city of China	All MCI	10,276	2,137	19.5 (18.8–20.3) †
					alzMCI	10,276	630	5.6 (5.2–6.0) †
					cvdMCI	10,276	392	3.4 (3.3–4.1) †
					vrfMCI	10,276	507	4.6 (4.2–5.0) †
					otherMCI	10,276	608	5.6 (5.2–6.1) †
M Guo, 2012[33]	China	UMIC	≥ 65	Non-demented residents of Xian	aMCI	264	35	13.26 (9.17-17.14)
Sosa, 2012[9]	Cuba	UMIC	≥65	Residents of urban and rural settings	aMCI	2,620	47	1.5 (1.0–1.9) †
	DR	UMIC			aMCI	1,767	25	1.3 (0.7–1.8) †
	Peru	UMIC			aMCI	1,767	55	2.6 (1.9–3.3) †
	Venezuela	UMIC			aMCI	1,820	22	1.0 (0.7–1.4) †
	Mexico	UMIC			aMCI	1,821	58	2.8 (2.0–3.6) †
	China	UMIC			aMCI	2,014	16	0.6 (0.3–0.9) †
	India	LMIC			aMCI	1,802	77	4.6 (3.7–5.4) †
Ogunniyi, 2016 [23]	Nigeria	UMIC	≥65	All MCI	6613	111	18.4 (14.9 – 21.9) *	
				aMCI-SD	613	47	n/a	

Author	Location	Income Class	Age (years)	Summary population characteristics	Mild cognitive impairment (MCI)			
					MCI definition	Total sample size	Cases	Prevalence % (95% CI)
				Residents of the Lalupon community, Oyo State (The IDEA Study)	aMCI-MD	613	45	n/a
					naMCI-SD	613	18	n/a
					naMCI-MD	613	1	n/a
Hai, 2012 [20]	China	UMIC	≥80	Non-demented residents of Chengdu	aMCI	202	61	30.2
INTERNATIONAL WORKING GROUP (IWG) ON MCI CRITERIA 2004 [97, 98, 100, 103] (n=14 studies)								
Ding, 2015[45]	China	UMIC	≥60	Non-demented community residents of Shanghai	All MCI	2,985	601	20.1 (18.7 - 21.5)
					aMCI	2,985	393	13.2 (12.0 - 14.4)
					naMCI	2,985	208	7.0 (6.1 - 7.9)
Fang, 2015[56]	China	UMIC	≥ 60	Non-demented residents of a community of Shanghai	aMCI	1059	137	12.90 (10.9-14.9)
Fang, 2009[54]	China	UMIC	≥ 60	Non-demented residents of Hangzhou	MCI	925	195	21.10 (18.45-23.58)
Tsoy, 2019[55]	Kazakhstan	UMIC	≥ 60	Residents from Almaty, Kazakhstan	MCI	662	201	30.4 (26.9-33.9)
Vanoh, 2016[53]	Malaysia	LMIC	≥60	Residents of four different states: Perak, Selangor, Kelantan and Johor (Towards Useful Ageing Study)	aMCI	1,993	315	15.8
Zhang, 2013[58]	China	UMIC	≥ 60	Non-demented residents of Taicang	aMCI	2460	450	18.29 (16.76-19.74)
Su, 2013 [52]	China	UMIC	≥60	Elderly of rural and urban areas in Xi'an	aMCI	796	145	18.2
Lee, 2012[47]	Malaysia	LMIC	≥60	Residents of Kuala Lumpur	All MCI	318	67	21.1
					aMCI	318	49	15.4
					naMCI	318	18	5.7
Janelidze, 2018[46]	Georgia	LMIC	≥65	Residents, without moderate to severe cognitive impairment, from urban (Tbilisi) and two rural areas (Kakheti and Imereti)	All MCI §	238	66	27.7
					aMCI	238	38	16.0
					naMCI	238	29	9.9
					aMCI-MD	238	8	3.3
					naMCI-MD	238	12	5.1
Ma, 2016[48]	China	UMIC	≥65	Non-demented residents of sixteen districts within the Tianjin urban boundary	All MCI	5,067	574	11.3 (8.2 - 14.4)
					aMCI-SD	5,067	227	4.5 (2.2 - 6.7)
					aMCI-MD	5,067	106	2.1 (0.8 - 3.4)
					naMCI-SD	5,067	214	4.2 (1.4 - 7.1)
					naMCI-MD	5,067	27	0.5 (0.3 - 0.8)
Pilleron, 2015[50]	CAR	LIC	≥65	Residents of Bangui and Nola	All MCI	9860	62	7.2
	ROC	LMIC		Residents of Brazzaville and Gamboma	All MCI	1913	56	6.1
Rao, 2018[51]	China	UMIC	≥65	Residents of Guangzhou	All MCI	2,111	299	14.2
					aMCI	2,111	258	12.2
					naMCI	2,111	41	2.0
Sun, 2016[57]	China	UMIC	≥ 65	Non-demented residents of Baotou	MCI	384	40	10.42 (7.36-13.32)
Paddick, 2015[49]	Tanzania	LIC	≥70	Residents of the Hai district	All MCI	296	46	6.3 (2.9 – 9.7)
EUROPEAN CONSORTIUM ON ALZHEIMER'S DISEASE CRITERIA 2006[105] (n=2 studies)								
Mohan, 2019[85]	India	LMIC	≥ 60	Residents from Thiruvananthapuram, Kerala	All MCI	426	111	26.1 (22.1-30.4)
Dimitrov, 2012 [88]	Bulgaria	UMIC	≥65	Residents from the city of Varna	All MCI	540	36	6.7 (4.6 - 8.8)
NIA-AA CRITERIA 2011[10] (n=2 studies)								
Vancampfort, 2017[11]	South Africa China Ghana India Mexico Russia	UMIC UMIC LMIC LMIC UMIC UMIC	≥50	Nationally representative sample of elderly without severe cognitive impairment (The WHO Study on Global Ageing and Adult Health)	All MCI	32,715	5,005	15.3 (14.4 - 16.3) **
Koyanagi, 2019[93]	South Africa	UMIC	≥50	Nationally representative sample from nine provinces across South Africa	All MCI	3672	312	8.5 (6.9-10.3)

Author	Location	Income Class	Age (years)	Summary population characteristics	Mild cognitive impairment (MCI)			
					MCI definition	Total sample size	Cases	Prevalence % (95% CI)
STUDY SPECIFIC CRITERIA FOR MCI (n= 13 studies)								
Das, 2007[91]	India	LMIC	≥50	Non-demented/non-depressed residents of Kolkata	All MCI	745	111	14.9 (12.2 - 18.0)
					aMCI (with/without complainers)	745	45	6.0 (4.4 – 8.1)
					aMCI (complainers only)	745	34	4.6 (3.1 – 6.3)
					mdMCI	745	66	8.9 (6.8 - 11.3)
Wang, 2013 [95]	China	UMIC	≥ 55	Non-demented residents of two cities of Ningxia province	aMCI	1033	199	19.26 (16.86-21.55)
Wang, 2016[94]	China	UMIC	≥ 55	Non-demented residents of Ningxia province	aMCI	2168	457	21.08 (19.4-22.7)
Huang, 2007[30]	China	UMIC	≥ 60	Non-demented residents of Shenzhen	MCI	410	88	21.46 (17.49-25.23)
Khedr, 2015[70]	Egypt	LMIC	≥60	Residents of Qena governorates in Southern Egypt	aMCI	691	12	1.7 (0.8 - 2.7)
Li, 2013 [74]	China	UMIC	≥ 60	Non-demented residents of Jinan	aMCI	1226	115	9.38 (7.75-10.93)
Lu, 2019[86]	China	UMIC	≥60	Residents of Ji County	In 2010			
					All MCI	5581	1278	22.9
					MCI-A		1060	19.0
					MCI-VD		128	2.3
					MCI-O		89	1.6
					In 2015			
					All MCI	5542	1541	27.8
					MCI-A		1019	18.4
MCI-VD	377	6.8						
MCI-O	149	2.7						
Wang, 2014[75]	China	UMIC	≥ 60	Non-demented residents of Zhoushan	MCI	1906	318	16.68 (15.01-18.27)
Wu, 2012[76]	China	UMIC	≥ 60	Non-demented residents of Xian	aMCI	1583	396	25.02 (22.88-27.04)
Zhao, 2015[79]	China	UMIC	≥ 60	Non-demented residents of Jilin province	aMCI	976	171	17.60 (15.14-19.78)
Zhou, 2016[80]	China	UMIC	≥ 60	Non-demented residents of Changji	MCI	804	223	27.74 (24.64-30.67)
Zhu, 2013[84]	China	UMIC	≥ 60	Non-demented residents of Zhejiang province	MCI	1211	251	20.70 (18.44-22.89)
Chu, 2015[89]	China	UMIC	≥ 65	Non-demented residents of a community of Shanghai	MCI	842	180	21.4 (18.6-24.0)
STUDY SPECIFIC CRITERIA FOR CIND/COGNITIVE IMPAIRMENT (n=10 studies)								
Brucki, 2014[59]	Brazil	UMIC	≥50	The Mamirauá and Amanã Sustainable Development Reserves, Amazonian Basin	CIND	163	10	6.1
Cesar, 2016[60]	Brazil	UMIC	≥60	Residents of rural and urban areas in the Tremembe area, State of Sao Paulo	CIND	630	135	19.5 (16.6 - 22.8)
Dominguez, 2018[61]	Philippines	LMIC	≥60	Residents of Marikina City	CIND	1,367	317	23.2
Lei, 2008[68]	China	UMIC	≥ 60	Normal cognitive and MCI residents from urban and rural areas of Guizhou province	CIND	4,323	665	15.4
Mejia-Arango, 2011[65]	Mexico	UMIC	≥60	Representative sample of elderly in Mexico (Mexican Health and Ageing Study)	CIND	6,847	1,719	28.7 ††
Zhang, 2014 ^{§§} [67]	China	UMIC	≥60	Residents of rural Ji County	CIND	5,550	1,295	23.3
Fei, 2009 [62]	China	UMIC	≥65	Residents of Taiyuan city	CIND	6,192	600	9.7 (9.6 - 9.8) ††
Guerchet, 2009[63]	Benin, West Africa	LIC	≥65	Residents in the rural commune of Djidja centre	CIND	502	34	6.8
Guerchet, 2010[64]	CAR	LIC	≥65	Older age residents of Bangui	CIND	496	124	25.0 (21.2 – 29.0)
	ROC	LMIC		Older aged residents of Brazzaville	CIND	520	98	18.8 (15.6 – 22.5)
Shi, 2013 ^{§§} [66]	China	UMIC	≥80	Residents of rural Ji County	CIND	626	297	47.4 (43.5 - 51.4)
CUT-OFF SCORE OF NEUROPSYCHOLOGICAL ASSESSMENT TOOL (n=3 studies)								

Author	Location	Income Class	Age (years)	Summary population characteristics	MCI definition	Mild cognitive impairment (MCI)		
						Total sample size	Cases	Prevalence % (95% CI)
Saha, 2010[92]	India	LMIC	≥50	Non-demented women, without history of neurological disorders, from a village of Singur block of Hoogly district, Kolkata	Cognitive impairment	179	76	42.4
Ruan, 2019[87]	China	UMIC	≥ 60	Residents from 20 communities in the Zhoujiaqiao Primary Health Service Area in Changning district, Shanghai,	MCI	5328	500	9.67
Inocian, 2016[69]	Philippines	LMIC	≥65	Elderly, with no diagnosed mental health conditions, from Cebu City	All MCI	120	76	63.3
DSM-IV CRITERIA [104] (n=8 studies)								
Hu, 2012[96]	China	UMIC	≥ 55	Non-demented residents of Nei Monggol	MCI	9266	1782	19.48 (18.43-19.99)
Guo, 2013[72]	China	UMIC	≥ 60	Non-demented residents of six towns of rural area of Hunan	aMCI	1367	139	10.17 (8.57-11.69)
Zhang, 2015[77]	China	UMIC	≥ 60	Non-demented residents of Taian	MCI	1971	651	33.03
Zhang and Zeng, 2014 [78]	China	UMIC	≥ 60	Non-demented residents of Changsha	aMCI	1764	229	16.27 (11.41-14.47)
Zhou, 2009[82]	China	UMIC	≥ 60	Non-demented residents of Xinjiang	aMCI	2986	205	10.21 (5.96-7.73)
Zhou, 2011[81]	China	UMIC	≥ 60	Non-demented residents of Ningbo	aMCI	1227	107	10.68 (7.14-10.22)
Zhu, 2009[83]	China	UMIC	≥ 60	Non-demented residents of Wulumuqi	aMCI	1511	148	9.79 (8.3-11.22)
Xiong, 2013[90]	China	UMIC	≥ 65	Non-demented residents of Tianjin	aMCI	2798	339	11.38 (10.91-13.26)

Notes

* Weighted prevalence for age using the World Health Organization world population estimates 2015. † Weighted prevalence for age, gender, and education level. ‡ Weighted prevalence calculated using reciprocal probability weighting based on the Sixth Nationwide Population Census in China, 2010. § Participants with 'all MCI' could be categorized in more than one MCI subtype. ¶ Weighted prevalence using the direct standardization method adjusted by age and sex to the total Chinese population (according to the census conducted in 2005). || Weighted prevalence for stratification and age according to the WHO standard population. ** Weighted prevalence according to the population structure as reported by the United Nations Statistical Division. †† Weighted prevalence to account for selection probabilities and controlling for age and sex. ††† Weighted prevalence to represent the total Mexican population. †††† The study from Shi, 2013 and Zhang, 2014 used data from the same cohort study.

Key

95%CI Confidence Interval

alzMCI MCI caused by prodromal Alzheimer's disease

aMCI Amnesic MCI

CAR Central African Republic

CIND Cognitive Impairment No Dementia

cvdMCI MCI resulting from cerebrovascular disease

DR Dominican Republic

LIC Low Income Country

LMIC Lower Middle Income Country

MCI Mild Cognitive Impairment

MCI-A Mild Cognitive Impairment with significant memory impairment

MCI-MD Multi Domain MCI

MCI-O non memory / nonvascular related types of mild cognitive impairment

MCI-SD Single Domain MCI

MCI-VD significant executive function impairment and relationship with cerebral vascular disease

naMCI Non-Amnesic MCI

NIA-AA National Institute on Aging and Alzheimer's Association

otherMCI MCI caused by other diseases

ROC Republic of Congo

UMIC Upper Middle Income Country

vrfMCI MCI with vascular risk factors

Figure 1 Study selection

Figure 2A Forest plot of MCI prevalence from studies using Petersen's criteria for Amnesic MCI (ordered by age). Note: red dotted line indicates 10% prevalence. **Key** 95%CI 95% Confidence Interval; aMCI Amnesic Mild Cognitive Impairment; DR Dominican Republic

Figure 2B Forest plot of MCI prevalence from studies using Petersen's criteria for All MCI (ordered by age). Note: red dotted line indicates 10% prevalence. **Key 95%CI** 95% Confidence Interval; **MCI** Mild Cognitive Impairment;

Figure 2C Forest plot of MCI prevalence from studies using the International Working Group criteria (ordered by age). Note: red dotted line indicates 10% prevalence. **Key** 95%CI 95% Confidence Interval; **IWG** International Working Group; **CAR** Central African Republic; **ROC** Republic of Congo

Figure 2D Forest plot of MCI prevalence from studies using definition of Cognitive Impairment No Dementia criteria (ordered by age). Note: red dotted line indicates 10% prevalence.
Key 95%CI 95% Confidence Interval; CAR Central African Republic; ROC Republic of Congo; CIND Cognitive Impairment No Dementia.

Figure 3 World Map showing each study site, number of studies in each site (n) and the reported MCI prevalence estimate(s)